CTLA4 and neoplasm: Interestingly, our patient with CMMRD had TMB-H but failed to respond to anti-PD-L1 monotherapy with CS1001–101 and combined therapy of anti-PD-1 and anti-CTLA-4 monoclonal antibodies, which may be due to tumor heterogeneity and MSS status.